Feinsod Matthew
SEC insider (Form 3/4/5 filer). CIK 0001716950. Chief Medical Officer at Kalaris Therapeutics, Inc. (KLRS). 4 reported Form 4/5 transactions since Sep 2024; latest on Mar 19, 2026. Located in BERKELEY HEIGHTS, NJ.
Companies Feinsod Matthew has filed insider reports for
- Kalaris Therapeutics, Inc. (KLRS): Officer, Chief Medical Officer
Feinsod Matthew
CIK: 0001716950
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Kalaris Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Mar 19, 2026KLRS
Kalaris Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
135K shares- - Apr 10, 2025KLRS
Kalaris Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
70.6K shares- - Apr 10, 2025KLRS
Kalaris Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
101K shares- - Mar 18, 2025KLRS
Kalaris Therapeutics, Inc.
AwardDirect4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 19, 2026 | KLRS Kalaris Therapeutics, Inc. | Award Stock Option (Right to Buy) | 135,000 | - | - | Direct |
| Apr 10, 2025 | KLRS Kalaris Therapeutics, Inc. | Award Stock Option (Right to Buy) | 70,551 | - | - | Direct |
| Apr 10, 2025 | KLRS Kalaris Therapeutics, Inc. | Award Stock Option (Right to Buy) | 101,000 | - | - | Direct |
| Mar 18, 2025 | KLRS Kalaris Therapeutics, Inc. | Award | 4,030 | - | - | Direct |
1-4 of 4 transactions